See more : PT Inti Bangun Sejahtera Tbk (IBST.JK) Income Statement Analysis – Financial Results
Complete financial analysis of DiaMedica Therapeutics Inc. (DMAC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DiaMedica Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Viking Holdings Ltd (VIK) Income Statement Analysis – Financial Results
- Xingye Alloy Materials Group Limited (0505.HK) Income Statement Analysis – Financial Results
- Payoneer Global Inc. (PAYOW) Income Statement Analysis – Financial Results
- Crypto 1 Acquisition Corp (DAOOU) Income Statement Analysis – Financial Results
- South West Pinnacle Exploration Limited (SOUTHWEST.BO) Income Statement Analysis – Financial Results
DiaMedica Therapeutics Inc. (DMAC)
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 160.62K | 25.74K | 25.68K | 33.88K |
| Cost of Revenue | 30.00K | 25.00K | 24.00K | 21.00K | 21.00K | 0.00 | 4.00K | 2.21K | 4.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -30.00K | -25.00K | -24.00K | -21.00K | -21.00K | 500.00K | -4.00K | -2.21K | -4.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 160.62K | 25.74K | 25.68K | 33.88K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 13.11M | 7.84M | 8.77M | 8.31M | 7.90M | 4.52M | 3.21M | 1.76M | 886.07K | 3.71M | 3.78M | 5.21M | 2.33M | 803.98K | 1.37M | 1.04M | 1.07M | 617.26K | 22.75K | 462.00K |
| General & Administrative | 8.16M | 6.16M | 4.88M | 4.39M | 3.69M | 2.74M | 1.31M | 718.05K | 423.35K | 1.12M | 2.54M | 2.53M | 2.08M | 1.30M | 1.00M | 618.54K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.16M | 6.16M | 4.88M | 4.39M | 3.69M | 2.74M | 1.31M | 718.05K | 423.35K | 1.12M | 2.54M | 2.53M | 2.08M | 1.30M | 1.00M | 618.54K | 1.38M | 192.37K | 177.78K | 168.91K |
| Other Expenses | 0.00 | 353.00K | 82.00K | -205.00K | -856.00K | -68.00K | 6.00K | 221.90K | 3.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.58K | -4.89K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.27M | 14.00M | 13.65M | 12.49M | 10.74M | 6.05M | 4.28M | 2.48M | 1.31M | 4.83M | 7.43M | 10.11M | 6.71M | 3.84M | 2.40M | 1.69M | 2.47M | 812.95K | 228.69K | 637.31K |
| Cost & Expenses | 21.27M | 14.00M | 13.65M | 12.49M | 10.74M | 6.05M | 4.28M | 2.48M | 1.31M | 4.83M | 7.43M | 10.11M | 6.71M | 3.84M | 2.40M | 1.69M | 2.47M | 812.95K | 228.69K | 637.31K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.73K | 1.74K | 10.54K | 14.73K | 41.03K | 51.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.25 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 48.38K | 43.96K | 0.00 | 7.73K | 2.72K | 12.57K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.60K | 36.59K |
| Depreciation & Amortization | 30.00K | 25.00K | 24.00K | 21.00K | 21.00K | 15.00K | 4.00K | 2.21K | 4.11K | 2.47K | 1.11M | 2.37M | 2.30M | 1.67M | 30.20K | 26.74K | 18.35K | 3.32K | 28.15K | 6.41K |
| EBITDA | -19.31M | -13.98M | -13.62M | -12.24M | -10.60M | -5.64M | -4.26M | -2.15M | -1.50M | -5.01M | -6.51M | -7.70M | -4.51M | -3.32M | -2.27M | -2.34M | -2.29M | -783.89K | -190.26K | -630.30K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,098.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,426.62% | -3,045.78% | -680.92% | -1,762.12% |
| Operating Income | -21.27M | -14.00M | -13.65M | -12.70M | -11.59M | -6.76M | -4.52M | -2.48M | -1.31M | -4.83M | -7.43M | -10.11M | -6.71M | -3.84M | -2.40M | -1.69M | -2.31M | -787.21K | -203.01K | -603.43K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,352.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,438.05% | -3,058.67% | -790.56% | -1,781.04% |
| Total Other Income/Expenses | 1.93M | 353.00K | 82.00K | 434.00K | 975.00K | 747.00K | 259.00K | 280.63K | -104.38K | -185.41K | -230.99K | 37.57K | -174.26K | -422.84K | 101.28K | -168.32K | 57.19K | -12.38K | 10.28K | 66.55K |
| Income Before Tax | -19.34M | -13.65M | -13.56M | -12.27M | -10.62M | -5.65M | -4.26M | -2.20M | -1.43M | -4.78M | -7.41M | -10.05M | -6.61M | -4.27M | -2.44M | -1.85M | -2.31M | 0.00 | -192.73K | -570.16K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,130.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,440.21% | 0.00% | -750.53% | -1,682.83% |
| Income Tax Expense | 43.00K | 28.00K | 28.00K | 27.00K | 31.00K | 80.00K | -9.00K | 22.31K | 12.45K | 42.28K | 7.73K | 2.72K | 12.57K | 499.08K | 41.69K | 163.43K | 20.20K | -9.19K | 17.87K | 69.86K |
| Net Income | -19.38M | -13.68M | -13.59M | -12.29M | -10.65M | -5.73M | -4.26M | -2.22M | -1.44M | -4.82M | -7.41M | -10.05M | -6.61M | -4.27M | -2.44M | -1.85M | -2.33M | -778.02K | -210.60K | -640.02K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,146.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,452.78% | -3,022.96% | -820.13% | -1,889.02% |
| EPS | -0.60 | -0.52 | -0.65 | -0.78 | -0.89 | -0.74 | -0.72 | -0.47 | -0.40 | -1.55 | -2.71 | -4.11 | -2.93 | -2.98 | -2.54 | -2.04 | -2.91 | -0.89 | -0.50 | -2.35 |
| EPS Diluted | -0.60 | -0.52 | -0.65 | -0.78 | -0.89 | -0.74 | -0.72 | -0.47 | -0.40 | -1.55 | -2.71 | -4.11 | -2.93 | -2.98 | -2.54 | -2.04 | -2.91 | -0.89 | -0.50 | -2.35 |
| Weighted Avg Shares Out | 32.57M | 26.44M | 20.77M | 15.68M | 11.99M | 7.74M | 5.94M | 4.74M | 3.62M | 3.11M | 2.73M | 2.45M | 2.26M | 1.43M | 960.48K | 909.72K | 802.30K | 876.03K | 420.15K | 272.16K |
| Weighted Avg Shares Out (Dil) | 32.57M | 26.44M | 20.77M | 15.68M | 11.99M | 7.74M | 5.94M | 4.74M | 3.62M | 3.11M | 2.73M | 2.45M | 2.26M | 1.43M | 960.48K | 909.72K | 802.30K | 876.03K | 420.15K | 272.16K |
DiaMedica Therapeutics to Present Research at the National Kidney Foundation's 2021 Spring Clinical Meetings
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Company will be presenting two abstracts at the National Kidney Foundation (NKF) 2021 Spring Clinical...
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2020 Results - Earnings Call Transcript
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2020 Results - Earnings Call Transcript
DiaMedica Therapeutics to Participate at Upcoming Investor Conferences
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company will participate in three upcoming investor conferences. Details of the company's participation are as...
DiaMedica Therapeutics to Report Fourth Quarter 2020 Financials and Provide a Business Update March 11, 2021
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its fourth quarter 2020 financial results will be released after the markets close on Wednesday, March...
DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that Dr. Harry Alcorn, its Chief Medical Officer will be presenting “CKD DM199 Research Update” at the 3rd Chronic...
Why Bausch Health, Oncolytics Biotech, And More Are Moving Today
iBio (NYSE: IBIO) shares are trading lower Wednesday after the company reported second-quarter earnings results. iBio's main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates.
DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that the last participant has been enrolled and is on treatment in the diabetic kidney disease Cohort of the Company's Phase 2 REDUX chronic kidney disease (CKD) study. The Company also announced...
DiaMedica Therapeutics Announces Successful Type B Meeting with FDA for the Study of DM199 in Patients with Acute Ischemic Stroke
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that it recently received written responses from the FDA following a Type B Pre-IND meeting request that the Company submitted in October 2020 regarding the Company's development plan for its product candidate, DM199,...
DiaMedica Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders, is pleased to announce that Rick Pauls, President and CEO of DiaMedica, will participate in a fireside...
DiaMedica Therapeutics to Participate in 11th Annual Craig-Hallum Alpha Select Conference
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for chronic kidney diseases and neurological disorders, today announced its President and CEO, Rick Pauls, and Chief Financial Officer, Scott Kellen, are scheduled to participate in...
Source: https://incomestatements.info
Category: Stock Reports